Kerr Douglas
An insider at 1 company in coverage, as reported on Form 4. SEC CIK 1814189. Latest Form 4 filed Oct 22, 2026.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| Dyne Therapeutics, Inc.DYN | Head of R&D and CMO, Officer | 2 | 2026-10-20 | 2026-10-20 |
Transactions: 2
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-20 | Dyne Therapeutics, Inc.Head of R&D and CMO, Officer | Grant or awardStock option (right to buy) | 12,000 | $0.00 | $0 | Form 4 |
| 2026-10-20 | Dyne Therapeutics, Inc.Head of R&D and CMO, Officer | Grant or award | 8,000 | $0.00 | $0 | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 31, 2026, 04:07 ET. Listed shows no prices and gives no investment advice.